Riproximin is a recently discovered type II ribosome inactivating protein with potential for treating cancer.
The development of new anticancer drugs is a salient problem and the traditional use of plants is a potentially rich source of information for detecting new molecules with antineoplastic activity. Riproximin is a recently detected cytotoxic type II ribosome inactivating protein with high selectivity for certain tumor cell lines. Its activity was recognized as the main component in a plant powder used by African healers for treating cancer. By ribulose bisphosphate carboxylase gene sequencing analysis, the powder was identified to be derived from the plant Ximenia americana. The cDNA sequence of riproximin was identified, the protein was modeled to contain one A- and a B-chain, respectively, and a reliable purification procedure from kernels of X. americana was established. Riproximin displays high but differential antiproliferative activity in a panel of human and rodent cancer cell lines, with concentrations inhibiting cell proliferation by 50% (IC50 values) that diverge by a factor of 100. Consistent antineoplastic activity was detected in colorectal and pancreatic cancer liver metastasis models in rats. The cytotoxic mechanism of action was determined to be based on cellular uptake of riproximin followed by its A-chain prompted depurination of the 28S ribosomal RNA and induction of unfolded protein response. Riproximin's specificity depended on its B-chain connected binding to cell surface glycans, the presence of which is crucial for subsequent internalization into cells and cytotoxicity. These N- and O-glycans include bi- and tri-antennary NA structures (NA2/NA3) as well as Tn3 structures (clustered Tn antigen). Riproximin was found to crosslink proteins with N- and O-glycan structure, thus indicating both types of binding sites on its B chain. Due to this crosslinking ability, riproximin is expected to show prominent cytotoxicity towards cells expressing both, NA2/NA3 and clustered Tn structures. Apart from the properties of riproximin, the plant X. americana has been known for some medical uses in traditional African medicine, including various types of infections.
German Cancer Research Center, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany.
Hassan
H
Adwan
German Cancer Research Center, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany.
Helene
H
Bayer
German Cancer Research Center, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany.
Asim
A
Pervaiz
German Cancer Research Center, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany.
Micah
M
Sagini
German Cancer Research Center, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany. Electronic address: m.berger@dkfz.de.
Martin R
MR
Berger
D000818:Animals; D000970:Antineoplastic Agents; D045744:Cell Line, Tumor; D006801:Humans; D051379:Mice; D031656:Olacaceae / Q000737:chemistry; D010940:Plant Proteins; D054790:Ribosome Inactivating Proteins, Type 2
D000970:Antineoplastic Agents; D010940:Plant Proteins; D054790:Ribosome Inactivating Proteins, Type 2; C511795:riproximin protein, Ximenia americana
Antineoplastic activity; Lectin; Ribosome inactivating protein type II; Riproximin; Unfolded protein response; Ximenia americana